Home > Insider Trading > Filing (0001209191-13-034981)

Filing Details

Accession Number:: 0001209191-13-034981
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-07-02 17:06:07
Reporting Period:: 2013-07-02

Filing Date:: 2013-07-02
Accepted Time:: 2013-07-02 17:06:07
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1509190	Aratana Therapeutics Inc.	PETX	Pharmaceutical Preparations (2834)	383826477

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1134655	Ansbert Gadicke	C/O Mpm Asset Management 200 Clarendon Street, 54Th Floor Boston MA 02116	No	No	Yes	No
1134657	Luke Evnin	C/O Mpm Asset Management 200 Clarendon Street, 54Th Floor Boston MA 02116	No	No	Yes	No
1180429	M Vaughn Kailian	C/O Mpm Asset Management 200 Clarendon Street, 54Th Floor Boston MA 02116	No	No	Yes	No
1356950	Paul James Scopa	C/O Mpm Asset Management 601 Gateway Boulevard, Suite 350 South San Francisco CA 94080	No	No	Yes	No
1473930	Todd Foley	C/O Mpm Asset Management 200 Clarendon Street, 54Th Floor Boston MA 02116	No	No	Yes	No
1482714	Mpm Bioventures V Gp Llc	C/O Mpm Asset Management 200 Clarendon Street, 54Th Floor Boston MA 02116	No	No	Yes	No
1482715	Mpm Bioventures V Llc	C/O Mpm Asset Management 200 Clarendon Street, 54Th Floor Boston MA 02116	No	No	Yes	No
1482716	Mpm Bioventures V, L.p.	C/O Mpm Asset Management 200 Clarendon Street, 54Th Floor Boston MA 02116	No	No	Yes	No
1541412	Mpm Asset Management Investors Bv5 Llc	C/O Mpm Asset Management 200 Clarendon Street, 54Th Floor Boston MA 02116	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-07-02	2,406,739	$0.00	2,823,173	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2013-07-02	802,246	$0.00	3,625,419	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2013-07-02	225,631	$0.00	3,851,050	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2013-07-02	500,000	$6.00	4,351,050	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2013-07-02	4,000,000	$0.00	2,406,739	$0.00
Common Stock	Series B Preferred Stock	Disposition	2013-07-02	1,333,333	$0.00	802,246	$0.00
Common Stock	Series C Preferred Stock	Disposition	2013-07-02	375,000	$0.00	225,631	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

The shares are held as follows: 2,316,738 by MPM BioVentures V, L.P. ("BV V") and 90,001 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin, Vaughn M. Kailian, James Paul Scopa, Todd Foley and John Vander Vort are the members of BV LLC. Mr. Vander Vort is a director of the Issuer and has separately filed a Form 4. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.6016847 of a share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The shares had no expiration date.
Immediately prior to the closing of the Issuer's initial public offering, the Issuer issued shares of its Common Stock to the holders of its Series A, B and C Preferred Stock in satisfaction of accumulated and unpaid dividends. Includes the following shares: 226,794 by BV V and 9,135 by AM BV5.
The shares are held as follows: 2,717,287 by BV V and 105,886 by AM BV5. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
The shares are held as follows: 772,246 by BV V and 30,000 by AM BV5. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
The shares are held as follows: 3,489,533 by BV V and 135,886 by AM BV5. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
The shares are held as follows: 217,194 by BV V and 8,437 by AM BV5. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
The shares are held as follows: 3,706,727 by BV V and 144,323 by AM BV5. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
The shares were purchased as follows: 481,302 by BV V and 18,698 by AM BV5.
The shares are held as follows: 4,188,029 by BV V and 163,021 by AM BV5. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
The shares of Series A Preferred Stock were held as follows: 3,850,418 by BV V and 149,582 by AM BV5. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respectivepecuniary interest therein.
Immediately.
Not applicable.
The shares of Series B Preferred Stock were held as follows: 1,283,473 by BV V and 49,860 by AM BV5. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respectivepecuniary interest therein.
The shares of Series C Preferred Stock were held as follows: 360,977 by BV V and 14,023 by AM BV5. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respectivepecuniary interest therein.